Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial
PaperCitations, authors & open-access status
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 36 citations, 2023 year and closed oa status.
36
Citations
2023
Year
closed
OA Status